Correction: Assessing the Value Contribution of Vyvgart® (Efgartigimod Alfa) in the Treatment of Generalized Myasthenia Gravis with Acetylcholine Receptor Antibody in Spain Through Multi-criteria Decision Analysis

Advances in Therapy 2026 Open access

Read full text
Authors: Elena Cortés‐Vicente, Antonio Guerrero, Carmina Díaz, Eva Martínez, Francisco José Toja-Camba, María R. Abad, José M. Serra, Jose L. Trillo, Celia Martín Machín, Alicia Gil
DOI: 10.1007/s12325-026-03532-4
Cited by: 0

Fields of Study & Subjects

Myasthenia Gravis and Thymoma Health Systems Economic Evaluations Quality of Life Pharmaceutical Economics and Policy

Publication details

Journal / source
Advances in Therapy
Volume
43
Issue
5
Pages
2317–2318
Publication date
12 March 2026
Language
EN